Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Yasmin H. Karimi, Catherine Thieblemont, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Wojciech Jurczak, Kim M. Linton, Martin Hutchings, Tycel Phillips, Umar Farooq, Won Seog Kim, Minh H. Dinh, Jagannath Ghosh, Rajash Pallai, Monica Wielgos-Bonvallet, Christian Eskelund, Pieternella J. Lugtenburg, Julie M. Vose

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S461-S462
Number of pages2
JournalClinical Lymphoma, Myeloma and Leukemia
Volume24
Issue numberS1
Early online date26 Aug 2024
DOIs
Publication statusPublished - Sept 2024

Keywords

  • All
  • Bispecific
  • Hematologic malignancy
  • large B-cell lymphoma
  • non-Hodgkin lymphoma

Cite this